ReviewBiomedicines2021
Catestatin as a Biomarker of Cardiovascular Diseases: A Clinical Perspective.
Review in Biomedicines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 33 citations in OpenAlex.
- Serum Catestatin Levels and Their Association with Pain Severity in Fibromyalgia Syndrome: A Cross-Sectional Case-Control Study.Journal of clinical medicine · 2026Article
- Serum Catestatin Level as a Novel Biomarker of Oral Lichen Planus.Medical sciences (Basel, Switzerland) · 2026Article
- Gingival crevicular fluid asprosin, adropin, and irisin hormone levels in the different periodontal status.Clinical oral investigations · 2026Article
- Temporal Dynamics of Catestatin Across Gestation: Links to Metabolic and Hemodynamic Adaptation.Life (Basel, Switzerland) · 2026Article
- Catestatin and Diabetic Retinopathy in Type 2 Diabetes Mellitus.Biomedicines · 2026Article
- New Cardiovascular Risk Biomarkers in Rheumatoid Arthritis: Implications and Clinical Utility-A Narrative Review.Biomedicines · 2025Review
- Catestatin in Cardiovascular Diseases.International journal of molecular sciences · 2025Review
- Catestatin and Advanced Glycation End-Products: Potential Indicators of Cardiovascular Risk in Hashimoto's Thyroiditis.Biomolecules · 2025Article
- Maternal Serum Catestatin Levels in Gestational Diabetes Mellitus: A Potential Biomarker for Risk Assessment and Diagnosis.Journal of clinical medicine · 2025Article
- The physiological anti-hypertensive peptide catestatin and its common human variant Gly364Ser: differential cardiovascular effects in a rat model of hypertension.Bioscience reports · 2024Article
- Analysis of Circulating Catestatin in Early Pregnancy: A Preliminary Investigation.Biomedicines · 2024Article
- Electrophysiological Mechanism of Catestatin Antiarrhythmia: Enhancement ofJournal of the American Heart Association · 2024Article
- Neurohumoral Activation in Heart Failure.International journal of molecular sciences · 2023Review
- Blood urea nitrogen to creatinine ratio and long-term survival in patients with chronic heart failure.European journal of medical research · 2023Article
- Chromogranin A and its derived peptides: potential regulators of cholesterol homeostasis.Cellular and molecular life sciences : CMLS · 2023Review
- Serum Catestatin Concentrations Are Increased in Patients with Atrial Fibrillation.Journal of cardiovascular development and disease · 2023Article
- Serum Catestatin Level as a Stratification Assessment Tool in Non-Critical COVID-19 Patients.International journal of environmental research and public health · 2023Article
- Serum Catestatin Levels Correlate with Ambulatory Blood Pressure and Indices of Arterial Stiffness in Patients with Primary Hypertension.Biomolecules · 2022Article
- Prognostic Value of Catestatin in Severe COVID-19: An ICU-Based Study.Journal of clinical medicine · 2022Article
- Serum catestatin levels in patients with rheumatoid arthritis.Scientific reports · 2022Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accounting for almost one-third of the global mortality, cardiovascular diseases (CVDs) represent a major global health issue. Emerging data suggest that most of the well-established mechanistic explanations regarding the cardiovascular pathophysiology are flawed, and cannot fully explain the progression and long-term effects of these diseases. On the other hand, dysregulation of the sympathetic nervous system (SNS) has emerged as an important player in the pathophysiology of CVDs. Even though upregulated SNS activity is an essential compensatory response to various stress conditions, in the long term, it becomes a major contributor to both cardiac dysfunction and vascular damage. Despite the fact that the importance of SNS hyperactivity in the setting of CVDs has been well-appreciated, its exact quantification and clinical application in either diagnostics or therapy of CVDs is still out of reach. Nevertheless, in recent years a number of novel laboratory biomarkers implicated in the pathophysiology of SNS activation have been explored. Specifically, in this review, we aimed to discuss the role of catestatin, a potent physiological inhibitor of catecholamine spillover that offers cardioprotective effects. Limited data indicate that catestatin could also be a reliable indirect marker of SNS activity and it is likely that high CST levels reflect advanced CV disease burden. Consequently, large-scale studies are required to validate these observations in the upcoming future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.